Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST-IgAN-1: Losartan in Early IgA Nephropathy
KCT0002916Phase 3Terminated
- Sponsor
- Yuhan
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of losartan in IgA nephropathy (IgAN), sponsored by Yuhan. Started Sep 2018; status: terminated.
02
Drugs
losartan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on KCT0002916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002916.